Fragile X Syndrome Recent News
For Rare Neural Diseases, Is Ovid Therapeutics The Right Team At The Right Time?
Catalysts Growing Like Weeds For Zynerba Next Quarter
It's High Time For Zynerba Positives: Investors Await 3 Key Mid-Stage Trial Reads On Cannabidiol ZYN002
Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
Zynerba Could See 3 Clinical Study Catalysts In 2017's First Half
A Higher Probability For Success Is Not Baked Into Zynerba's Valuation